Investment
Features
FeesSafety
Academy
More
Pluang+

Compare Bristol-Myers Squibb Co (BMY) vs Goodyear Tire & Rubber Co (GT) Price & Performance

Bristol-Myers Squibb CoTrade
Goodyear Tire & Rubber CoTrade

Price performance (Past 24H)

Key statistics

Bristol-Myers Squibb Co vs Goodyear Tire & Rubber Co — how do they compare? Bristol-Myers Squibb Co trades at $63.95 (market cap $129.94B), while Goodyear Tire & Rubber Co trades at $6.11 (market cap $1.75B). The key difference: Bristol-Myers Squibb Co is far larger — about 74.3× Goodyear Tire & Rubber Co's market cap, and Bristol-Myers Squibb Co pays a 3.96% dividend while Goodyear Tire & Rubber Co pays none. Which is the better fit depends on your goals.

BMYGT
Market Cap
$129.94B$1.75B
Sector
HealthConsumer Cyclical
52-Week High
$65.89$10.54
52-Week Low
$42.60$5.58
Enterprise Value
$163.92B$9.11B
Dividend Yield
3.96%

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

Bristol-Myers Squibb Co

Bristol Myers Squibb (BMY) trades at $63.88, down 1.48% on the day, with strong technical momentum indicated by bullish moving averages and ADX signals. The company demonstrates robust fundamentals with a 14.01 P/E ratio, 18.87% net income margin, and consistent earnings beats in recent quarters. Recent developments include a $2.3 billion manufacturing investment in Houston and strategic AI collaboration with Schrödinger.

BMY presents a compelling investment case with attractive valuation metrics and strong profitability, though investors face risks from patent expirations and debt levels. Analyst consensus suggests 7% upside to the $68.56 price target, with the stock offering dividend income alongside growth potential from pipeline developments and potential M&A activity.

Goodyear Tire & Rubber Co

The Goodyear Tire & Rubber Company (GT) trades at $5.98, down 0.83% on the day, reflecting ongoing pressure from declining revenue and a significant net loss of $1.72 billion in 2025. Technical indicators are bearish, with moving averages signaling a downtrend, while fundamentals show a low P/E of 4.69 and P/B of 0.62, suggesting potential undervaluation despite negative profitability metrics like a -14.37% net income margin. Recent Q2 2026 earnings showed a loss of $0.61 per share, beating expectations but highlighting volume challenges.

GT presents a high-risk opportunity with its cheap valuation offset by weak earnings and cash flow volatility. Analyst sentiment is mixed, with 34.62% buy ratings, but risks include persistent volume declines, high debt, and competitive pressures. The stock's outlook hinges on operational improvements and market stabilization, making it speculative for value investors.

Returns comparison

Trailing returns across standard periods

Top news

Latest headlines on both assets

About Bristol-Myers Squibb Co

Bristol-Myers Squibb discovers, develops, and markets drugs for various therapeutic areas, such as cardiovascular, cancer, and immune disorders. A key focus for Bristol is immuno-oncology, where the firm is a leader in drug development. Unlike some of its more diversified peers, Bristol has exited several nonpharmaceutical businesses to focus on branded specialty drugs, which tend to support strong pricing power.

Read more on BMY

About Goodyear Tire & Rubber Co

Goodyear Tire & Rubber Co manufactures and sells a variety of rubber tires under the Goodyear brand name. The firm's tires are used for automobiles, trucks, buses, aircraft, motorcycles, mining equipment, farm equipment, and industrial equipment.

Read more on GT